WVE
Wave Life Sciences Ltd. NASDAQ$7.47
Pre-mkt
$7.49
+0.27%
Mkt Cap $1.4B
52w Low $5.02
14.7% of range
52w High $21.73
50d MA $10.04
200d MA $10.21
P/E (TTM)
-6.0x
EV/EBITDA
-11.7x
P/B
2.4x
Debt/Equity
0.0x
ROE
-35.9%
P/FCF
-15.3x
RSI (14)
—
ATR (14)
—
Beta
-1.32
50d MA
$10.04
200d MA
$10.21
Avg Volume
4.2M
About
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company a…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 | TNS | -0.34 | -0.13 | +61.8% | 7.52 | -1.6% | -6.2% | -6.1% | -2.7% | — | — | — |
| Feb 26, 2026 | TNS | -0.28 | -0.30 | -7.1% | 15.36 | -1.8% | -9.3% | -9.8% | -12.5% | -10.7% | -14.1% | — |
| Nov 10, 2025 | TNS | -0.30 | -0.32 | -6.7% | 7.05 | -0.7% | +3.0% | -1.3% | -5.4% | +0.4% | +1.4% | — |
| Jul 30, 2025 | TNS | -0.29 | -0.31 | -6.9% | 8.16 | -1.6% | -0.7% | +5.8% | +7.2% | +8.3% | +4.8% | — |
| May 8, 2025 | TNS | -0.27 | -0.29 | -7.4% | 6.54 | -0.2% | +0.8% | +0.9% | -2.3% | -2.9% | -3.7% | — |
| Mar 4, 2025 | TNS | -0.17 | 0.17 | +200.0% | 11.23 | -0.9% | -5.9% | -9.3% | -16.3% | -16.4% | -7.4% | — |
| Nov 12, 2024 | TNS | -0.28 | -0.47 | -67.9% | 15.89 | +2.6% | -1.3% | -5.6% | -14.0% | -19.1% | -10.6% | — |
| Aug 8, 2024 | TNS | -0.21 | -0.25 | -19.0% | 5.74 | +0.2% | -5.7% | -6.4% | -3.0% | -3.0% | +1.2% | — |
| May 9, 2024 | TNS | -0.21 | -0.24 | -14.3% | 5.76 | +2.4% | -2.4% | -1.2% | +1.4% | +2.4% | +2.4% | — |
| Mar 6, 2024 | TNS | -0.23 | -0.15 | +34.8% | 6.29 | +1.7% | +8.4% | +7.8% | +8.1% | +5.9% | +8.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.05 | $7.05 | +0.0% | +0.1% | +3.8% | — | — | — |
| Apr 29 | Truist | Reiterates | Buy | $15 | $7.52 | $7.40 | -1.6% | -6.2% | -6.1% | -2.7% | — | — |
| Apr 29 | Truist | Maintains | Buy → Buy | — | $7.52 | $7.40 | -1.6% | -6.2% | -6.1% | -2.7% | — | — |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.26 | $7.29 | +0.4% | +1.8% | +4.5% | +0.8% | +3.2% | +4.4% |
| Mar 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $6.20 | $6.02 | -2.9% | +2.7% | +6.8% | +16.9% | +10.2% | +17.4% |
| Mar 27 | BofA Securities | Maintains | Buy → Buy | — | $6.20 | $6.02 | -2.9% | +2.7% | +6.8% | +16.9% | +10.2% | +17.4% |
| Mar 25 | Mizuho | Maintains | Outperform → Outperform | — | $11.63 | $12.18 | +4.7% | +5.8% | -46.7% | -45.2% | -43.1% | -37.7% |
| Mar 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.29 | $13.54 | +1.9% | +3.5% | +5.9% | +0.5% | -2.0% | -6.6% |
| Mar 6 | Wedbush | Maintains | Outperform → Outperform | — | $13.20 | $13.22 | +0.2% | -0.6% | +0.7% | +4.2% | +6.7% | +1.1% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.93 | $13.65 | -2.0% | -0.6% | -3.5% | -1.6% | -5.2% | -5.8% |
Recent Filings
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences issued a press release as disclosed in its 8-K filing, though the specific announcement details require review of the attached exhibit for investor impact assessment.
Apr 28
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences filed a proxy statement regarding Wave-Singapore, indicating shareholders will vote on a significant corporate action, with documents available on the SEC and company websites.
Apr 21
8-K
Unknown — 8-K Filing
Wave Life Sciences is redomiciling from Singapore to Delaware, likely improving U.S. investor accessibility and corporate governance, which could enhance stock liquidity and institutional investment appeal.
Apr 15
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
WVE announced a material event via press release, likely involving significant business developments or financial results that could materially impact the stock's price and warrant immediate investor review of the full announcement.
Mar 26
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences issued a press release, though the specific announcement details are not provided in this summary excerpt.
Feb 26
8-K
Wave Life Sciences Ltd. -- 8-K Filing
Wave Life Sciences regained full development and commercialization rights to WVE-006 from GSK, giving the company control of this potential alpha-1 antitrypsin deficiency treatment.
Feb 2
Data updated apr 27, 2026 10:13am
· Source: massive.com